View Future GrowthPsyched Wellness 過去の業績過去 基準チェック /06Psyched Wellnessの収益は年間平均-2.6%の割合で減少していますが、 Personal Products業界の収益は年間 減少しています。収益は年間0.01% 56.1%割合で 増加しています。主要情報-2.59%収益成長率20.67%EPS成長率Personal Products 業界の成長20.87%収益成長率56.12%株主資本利益率-305.89%ネット・マージン-882.36%前回の決算情報28 Feb 2026最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Mar 12Psyched Wellness Ltd. announced that it expects to receive CAD 1.719307 million in funding from Gotham Green Partners, LLC and affiliates and or co-investors of Gotham GreenPsyched Wellness Ltd. announced that it has entered into a non-binding term sheet with returning investors Gotham Green Fund I, L.P. and Gotham Green Fund I (Q), L.P. pursuant to which the Company shall complete a non-brokered private placement and will issue 170,228,410 common shares and common share purchase warrants for aggregate gross proceeds of up to CAD 1,719,306.941 on March 11, 2026. The Offering will be led by Gotham Green, and it may include affiliates and/or co-investors of Gotham Green. The company will raise proceeds in two tranches of up to CAD 859,653.47 each, subject to closing conditions. The Offering will consist of issuances of Common Shares at a price of CAD 0.0101 per Common Share and Warrants at a price of CAD 0.005 per Warrant. Each Warrant will entitle the holder thereof to acquire one additional Common Share at a price of CAD 0.0051 per Additional Share at any time on or before the Warrant expiry date, set sixty (60) months following the applicable closing date. The Company has obtained approval from the Canadian Securities Exchange (the "CSE") to issue the Common Shares and Warrants at a price lower than CAD 0.05 as the Offering Price is above the volume weighted average trading price of the Common Shares on the CSE for the 20 trading day period ending March 10, 2026. The Offering will be offered for purchase and sale to investors in the United States on a private placement basis. The initial tranche is scheduled to close on or about March 18, 2026 (the "Tranche 1 Closing Date") for aggregate gross proceeds of CAD 859,653.47 (the "Initial Tranche"). Subject to the policies of the CSE, closing of the second and final tranche could be for up to CAD 859,653.47 ("Tranche 2"). The Investor Group has no obligation to fund Tranche 2, and may elect to complete Tranche 2 in whole or in part or not at all in the Investor Group's sole discretion. Additionally, the closing of Tranche 2 shall be subject to satisfactory completion of due diligence in the Investor Group's sole discretion. All securities issued under the Offering will be subject to a four month and one day hold period from the applicable closing date and applicable legends as required pursuant to the U.S. Securities Act. Closing of the Offering is subject to customary closing conditions, including the approval of the CSE.お知らせ • Nov 27Psyched Wellness Ltd. Launches CalmerPsyched Wellness Ltd. announced the launch of Calmer, a new product offering that delivers twice the potency of its product, Calm. The Company has also enhanced the flavour profile of Calm in both the 30 ml and 60 ml formats, reducing the mushroom taste while maintaining potency and consumer experience. The launch coincides with Psyched's Black Friday promotion, offering customers a 40% discount site-wide (excluding merch) through December 1, 2025.お知らせ • Apr 10AME Wellness Inc. Working with its Advisors, Zerkalo LLC Completes an Initial Pilot Run of New Dietary Supplement in Form of 4 oz ShotPsyched Wellness Ltd. announced that its US subsidiary, AME Wellness Inc., working with its advisors, Zerkalo LLC, have completed an initial pilot run of new dietary supplement in form of a 4 oz shot. The purpose of this pilot run is to beta test the shot with a select target group of consumers and gather feedback on the taste, the effect, and marketing data relating to the product. As part of this process, the Company will stress test its website, 3pl and shipping process to ensure that its fulfilment capabilities are in place in advance of the product launch.お知らせ • Mar 04Psyched Wellness Ltd., Annual General Meeting, May 15, 2025Psyched Wellness Ltd., Annual General Meeting, May 15, 2025.お知らせ • Nov 27Psyched Wellness Ltd. Announces Resignation of Harrison Aaron as DirectorPsyched Wellness Ltd. announced that Harrison Aaron, a nominee of Gotham Green Partners, LLC ("Gotham Green"), has resigned as a director of the Company effective November 22, 2024.お知らせ • Jun 22Psyched Wellness Ltd. Announces Board ChangesPsyched Wellness Ltd. announced that Amanda Galbraith has resigned as a director of the Company effective June 19, 2023. The Company also announced that Harrison Aaron has been appointed as director effective June 19, 2023. Harrison Aaron: Mr. Aaron is a Principal at Santa Monica based investment firm Gotham Green Partners, LLC ("Gotham Green") having joined the firm in early 2019. During his time at Gotham Green, in addition to helping lead the firm's broader investment efforts, he co-founded cannabis e-commerce retail and delivery business Amuse.com (currently serving Los Angeles, the Bay Area, and Sacramento), as well as co-founding Sandland Sleep (SandlandSleep.com), nationwide seller of highly-effective natural sleep aids, and is currently serving on the boards of both companies, as well as serving on the boards of VIOLA Brands and Engin Sciences. Prior to his time at Gotham Green, from 2013 to 2019, he covered the consumer sector as a senior analyst on the investment team at NYC-based JANA Partners, a multi-billion-dollar hedge fund investing in companies undergoing, or with the potential to undergo, value-unlocking changes. Mr. Aaron began his career on Goldman Sachs' Hedge Fund Strategies and Cross Asset Sales teams from 2009-2013, after graduating magna cum laude and Phi Beta Kappa from Colgate University, with high honors in Mathematical Economics.New Risk • Jun 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$8.63m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (CA$72k revenue, or US$54k). Market cap is less than US$10m (US$8.63m market cap).お知らせ • May 20Psyched Wellness Ltd., Annual General Meeting, Jul 11, 2023Psyched Wellness Ltd., Annual General Meeting, Jul 11, 2023.お知らせ • Feb 03Psyched Wellness Ltd. Adds New Bottle Size for Their Amanita Muscaria Extract CalmPsyched Wellness Ltd. announced that they will be launching a new larger bottle size for their proprietary Amanita Muscaria Extract (AME-1) product Calm, on February 28th 2023. The new size will provide customers with double the servings per bottle, in a 60ml package. Calm is the first legal Amanita Muscaria extract available for sale in the USA.お知らせ • Aug 01Psyched Wellness Ltd. announced that it has received CAD 4.05606 million in fundingOn July 31, 2020, Psyched Wellness Ltd. (OTCPK:DCNP.F) closed the transaction. The company issued 1,875,595 common shares for gross proceeds of CAD $187,559.5 in its final tranche.お知らせ • Jul 30Psyched Wellness Corp. acquired Duncan Park Holdings Corporation (OTCPK:DCNP.F) in a reverse merger transaction.Psyched Wellness Corp. acquired Duncan Park Holdings Corporation (OTCPK:DCNP.F) in a reverse merger transaction on May 5, 2020. Pursuant to the acquisition Duncan Park Holdings Corporation acquired all of the outstanding common shares of Psyched Wellness in exchange for common shares of the Duncan Park Holdings Corporation on a one for one basis. The shareholders of Psyched Wellness were issued an aggregate of 18 million common shares. Duncan Park Holdings Corporation became the sole shareholder of all of the outstanding securities of Psyched Wellness and will carry on Psyched's business. As part of the transaction, Duncan Park Holdings Corporation will seek shareholder approval at its next meeting of shareholders to approve a change to the Duncan Park Holdings Corporation name to Psyched Wellness Ltd. or such other name. As a result of the transaction, Jeffrey Stevens, will be the Director and Chief Executive Officer, Keith Li, will be the Chief Financial Officer and Corporate Secretary, David Shisel, will be the Chief Operating Officer, Michael Nederhoff, will be the Director (Chairman), Terry Booth, Nicholas Kadysh, and Chris Hazelton, will act as the Directors of the combined company. Psyched Wellness Corp. completed the acquisition of Duncan Park Holdings Corporation (OTCPK:DCNP.F) in a reverse merger transaction on May 5, 2020.収支内訳Psyched Wellness の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:PSYC.F 収益、費用、利益 ( )CAD Millions日付収益収益G+A経費研究開発費28 Feb 261-63230 Nov 250-53231 Aug 250-41331 May 250-52328 Feb 251-43230 Nov 241-43231 Aug 241-55031 May 240-44029 Feb 240-33030 Nov 230-33031 Aug 230-32031 May 230-43028 Feb 230-43130 Nov 220-43131 Aug 220-43131 May 220-43128 Feb 220-54130 Nov 210-44131 Aug 210-54131 May 210-54128 Feb 210-33030 Nov 200-22031 Aug 200-11031 May 20000029 Feb 200000質の高い収益: PSYC.Fは現在利益が出ていません。利益率の向上: PSYC.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: PSYC.Fは利益が出ておらず、過去 5 年間で損失は年間2.6%の割合で増加しています。成長の加速: PSYC.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: PSYC.Fは利益が出ていないため、過去 1 年間の収益成長をPersonal Products業界 ( -21.6% ) と比較することは困難です。株主資本利益率高いROE: PSYC.Fは現在利益が出ていないため、自己資本利益率 ( -305.89% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YHousehold 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 19:21終値2026/05/21 00:00収益2026/02/28年間収益2025/11/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Psyched Wellness Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 12Psyched Wellness Ltd. announced that it expects to receive CAD 1.719307 million in funding from Gotham Green Partners, LLC and affiliates and or co-investors of Gotham GreenPsyched Wellness Ltd. announced that it has entered into a non-binding term sheet with returning investors Gotham Green Fund I, L.P. and Gotham Green Fund I (Q), L.P. pursuant to which the Company shall complete a non-brokered private placement and will issue 170,228,410 common shares and common share purchase warrants for aggregate gross proceeds of up to CAD 1,719,306.941 on March 11, 2026. The Offering will be led by Gotham Green, and it may include affiliates and/or co-investors of Gotham Green. The company will raise proceeds in two tranches of up to CAD 859,653.47 each, subject to closing conditions. The Offering will consist of issuances of Common Shares at a price of CAD 0.0101 per Common Share and Warrants at a price of CAD 0.005 per Warrant. Each Warrant will entitle the holder thereof to acquire one additional Common Share at a price of CAD 0.0051 per Additional Share at any time on or before the Warrant expiry date, set sixty (60) months following the applicable closing date. The Company has obtained approval from the Canadian Securities Exchange (the "CSE") to issue the Common Shares and Warrants at a price lower than CAD 0.05 as the Offering Price is above the volume weighted average trading price of the Common Shares on the CSE for the 20 trading day period ending March 10, 2026. The Offering will be offered for purchase and sale to investors in the United States on a private placement basis. The initial tranche is scheduled to close on or about March 18, 2026 (the "Tranche 1 Closing Date") for aggregate gross proceeds of CAD 859,653.47 (the "Initial Tranche"). Subject to the policies of the CSE, closing of the second and final tranche could be for up to CAD 859,653.47 ("Tranche 2"). The Investor Group has no obligation to fund Tranche 2, and may elect to complete Tranche 2 in whole or in part or not at all in the Investor Group's sole discretion. Additionally, the closing of Tranche 2 shall be subject to satisfactory completion of due diligence in the Investor Group's sole discretion. All securities issued under the Offering will be subject to a four month and one day hold period from the applicable closing date and applicable legends as required pursuant to the U.S. Securities Act. Closing of the Offering is subject to customary closing conditions, including the approval of the CSE.
お知らせ • Nov 27Psyched Wellness Ltd. Launches CalmerPsyched Wellness Ltd. announced the launch of Calmer, a new product offering that delivers twice the potency of its product, Calm. The Company has also enhanced the flavour profile of Calm in both the 30 ml and 60 ml formats, reducing the mushroom taste while maintaining potency and consumer experience. The launch coincides with Psyched's Black Friday promotion, offering customers a 40% discount site-wide (excluding merch) through December 1, 2025.
お知らせ • Apr 10AME Wellness Inc. Working with its Advisors, Zerkalo LLC Completes an Initial Pilot Run of New Dietary Supplement in Form of 4 oz ShotPsyched Wellness Ltd. announced that its US subsidiary, AME Wellness Inc., working with its advisors, Zerkalo LLC, have completed an initial pilot run of new dietary supplement in form of a 4 oz shot. The purpose of this pilot run is to beta test the shot with a select target group of consumers and gather feedback on the taste, the effect, and marketing data relating to the product. As part of this process, the Company will stress test its website, 3pl and shipping process to ensure that its fulfilment capabilities are in place in advance of the product launch.
お知らせ • Mar 04Psyched Wellness Ltd., Annual General Meeting, May 15, 2025Psyched Wellness Ltd., Annual General Meeting, May 15, 2025.
お知らせ • Nov 27Psyched Wellness Ltd. Announces Resignation of Harrison Aaron as DirectorPsyched Wellness Ltd. announced that Harrison Aaron, a nominee of Gotham Green Partners, LLC ("Gotham Green"), has resigned as a director of the Company effective November 22, 2024.
お知らせ • Jun 22Psyched Wellness Ltd. Announces Board ChangesPsyched Wellness Ltd. announced that Amanda Galbraith has resigned as a director of the Company effective June 19, 2023. The Company also announced that Harrison Aaron has been appointed as director effective June 19, 2023. Harrison Aaron: Mr. Aaron is a Principal at Santa Monica based investment firm Gotham Green Partners, LLC ("Gotham Green") having joined the firm in early 2019. During his time at Gotham Green, in addition to helping lead the firm's broader investment efforts, he co-founded cannabis e-commerce retail and delivery business Amuse.com (currently serving Los Angeles, the Bay Area, and Sacramento), as well as co-founding Sandland Sleep (SandlandSleep.com), nationwide seller of highly-effective natural sleep aids, and is currently serving on the boards of both companies, as well as serving on the boards of VIOLA Brands and Engin Sciences. Prior to his time at Gotham Green, from 2013 to 2019, he covered the consumer sector as a senior analyst on the investment team at NYC-based JANA Partners, a multi-billion-dollar hedge fund investing in companies undergoing, or with the potential to undergo, value-unlocking changes. Mr. Aaron began his career on Goldman Sachs' Hedge Fund Strategies and Cross Asset Sales teams from 2009-2013, after graduating magna cum laude and Phi Beta Kappa from Colgate University, with high honors in Mathematical Economics.
New Risk • Jun 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$8.63m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (CA$72k revenue, or US$54k). Market cap is less than US$10m (US$8.63m market cap).
お知らせ • May 20Psyched Wellness Ltd., Annual General Meeting, Jul 11, 2023Psyched Wellness Ltd., Annual General Meeting, Jul 11, 2023.
お知らせ • Feb 03Psyched Wellness Ltd. Adds New Bottle Size for Their Amanita Muscaria Extract CalmPsyched Wellness Ltd. announced that they will be launching a new larger bottle size for their proprietary Amanita Muscaria Extract (AME-1) product Calm, on February 28th 2023. The new size will provide customers with double the servings per bottle, in a 60ml package. Calm is the first legal Amanita Muscaria extract available for sale in the USA.
お知らせ • Aug 01Psyched Wellness Ltd. announced that it has received CAD 4.05606 million in fundingOn July 31, 2020, Psyched Wellness Ltd. (OTCPK:DCNP.F) closed the transaction. The company issued 1,875,595 common shares for gross proceeds of CAD $187,559.5 in its final tranche.
お知らせ • Jul 30Psyched Wellness Corp. acquired Duncan Park Holdings Corporation (OTCPK:DCNP.F) in a reverse merger transaction.Psyched Wellness Corp. acquired Duncan Park Holdings Corporation (OTCPK:DCNP.F) in a reverse merger transaction on May 5, 2020. Pursuant to the acquisition Duncan Park Holdings Corporation acquired all of the outstanding common shares of Psyched Wellness in exchange for common shares of the Duncan Park Holdings Corporation on a one for one basis. The shareholders of Psyched Wellness were issued an aggregate of 18 million common shares. Duncan Park Holdings Corporation became the sole shareholder of all of the outstanding securities of Psyched Wellness and will carry on Psyched's business. As part of the transaction, Duncan Park Holdings Corporation will seek shareholder approval at its next meeting of shareholders to approve a change to the Duncan Park Holdings Corporation name to Psyched Wellness Ltd. or such other name. As a result of the transaction, Jeffrey Stevens, will be the Director and Chief Executive Officer, Keith Li, will be the Chief Financial Officer and Corporate Secretary, David Shisel, will be the Chief Operating Officer, Michael Nederhoff, will be the Director (Chairman), Terry Booth, Nicholas Kadysh, and Chris Hazelton, will act as the Directors of the combined company. Psyched Wellness Corp. completed the acquisition of Duncan Park Holdings Corporation (OTCPK:DCNP.F) in a reverse merger transaction on May 5, 2020.